DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...
DexCom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, DexCom has captured an impressive slice of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The Dexcom G7 15 Day ...
However, Oppenheimer downgraded DexCom from Outperform to Perform, pointing to ongoing accuracy and performance challenges with the G7 device. Adding to the concerns, Hunterbrook Media released a ...
In other recent news, DexCom has been the focus of various analyst reports and market reactions regarding its G7 continuous glucose monitoring device. UBS maintained its Buy rating for DexCom, setting ...
In December, online rumors hinted at the fact that Dexcom may be planning to sunset its G6 CGM sensor model. The company has now started to notify patients of the discontinuation plan. The company ...
Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results